Skip to main content

Protalix BioTherapeutics, Inc.

PLX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001006281

No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.

Superinvestors holding PLX, Q2 2026

See all superinvestors

No superinvestor reported holding PLX in Q2 2026.